Product Information
TOPIRAMATE ER 50 MG CAPSULE is a generic product labeled by Endo USA Inc., priced at $6.1739 per EA under NDC 10370036601. Its NADAC has been published 170 times since Jul 5, 2023.
FDA first approved this application on Mar 1, 2023. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/1
Manufacturer
Endo USA Inc.NDC
10370036601
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA205976FDA Approved
3/1/2023
TE Code
AB1
On Market Since
5/26/2023
Pharmacological Classes
Price Statistics
The NADAC for TOPIRAMATE ER 50 MG CAPSULE has been published 170 times since Jul 5, 2023, and over the history we have for it it has declined 50.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.1739 per EA |
|---|---|
| All-time high | $12.4518 (Jul 12, 2023) |
| All-time low | $5.3769 (Nov 20, 2024) |
| 52-week high | $6.7514 |
| 52-week low | $5.7954 |
| Median price | $6.8108 |
| Average price | $7.3771 |
| Largest weekly change | -28.1% (Feb 21, 2024) |
| Weeks tracked | 170 |
| Tracking since | Jul 5, 2023 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 49% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPIRAMATE ER 50 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TOPIRAMATE ER 50 MG CAPSULE, manufactured by Endo USA Inc., is $6.1739 per EA (NDC 10370036601), effective Sep 30, 2026.
How has the price of TOPIRAMATE ER 50 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TOPIRAMATE ER 50 MG CAPSULE has declined 50.4%. It has been tracked across 170 weekly CMS publications since Jul 5, 2023.
What are the highest and lowest recorded NADAC prices for TOPIRAMATE ER 50 MG CAPSULE?
Since Jul 5, 2023, the NADAC for TOPIRAMATE ER 50 MG CAPSULE has ranged from a low of $5.3769 (Nov 20, 2024) to a high of $12.4518 (Jul 12, 2023), with a median of $6.8108 per EA.
Are there cheaper alternatives to TOPIRAMATE ER 50 MG CAPSULE?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 50 MG SPRINKL CAP, is $3.1462 per EA — about 49% below TOPIRAMATE ER 50 MG CAPSULE.
Who manufactures TOPIRAMATE ER 50 MG CAPSULE?
TOPIRAMATE ER 50 MG CAPSULE (NDC 10370036601) is labeled by Endo USA Inc., and CMS classifies it as a generic product.